Part of the Internal Medicine Commons
Regarding: Humar et al. The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients, C. Da Cunha-Bang, M. Iversen, S. A. Mortensen, A. Rasmussen, H. Sengeløv, S. S. Sørensen, J. Lundgren Maura Iversen
Advanced Search
